Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7
摩根士丹利維持對Cytek Biosciences的同等權重,將目標股價下調至7美元
Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $8 to $7.
摩根士丹利分析師Tejas Savant維持Cytek Biosciences(納斯達克股票代碼:CTKB)的權重持平,並將目標股價從8美元下調至7美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。